Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticoagulant drugs Clear all
Completed Phase 2 Interventional

Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

NCT05837338
View directory record Official record
Conditions
Wound Bleeding
Interventions
BXP154, Placebo
Drug
Lead sponsor
Bio 54, LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 13, 2026, 9:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DOAC ADRs Retrospective Study on Genetic Variations

NCT04580589
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Terminated Phase 3 Interventional

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055
View directory record Official record
Conditions
Radial Artery Occlusion
Interventions
Rivaroxaban 15 MG Oral Tablet [Xarelto]
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Results available

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

NCT03864406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cobicistat, Darunavir/Cobicistat, Rivaroxaban
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Terminated Not applicable Interventional Results available

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

NCT02447926
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 13, 2026, 9:14 PM EDT
Not listed Not applicable Interventional

Neurostimulation of Spinal Nerves That Affect the Heart

NCT01124136
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Neurostimulation + Medication Management (Standard of Care), Standard of Care (Control)
Device · Drug
Lead sponsor
Jerry Estep, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 13, 2026, 9:14 PM EDT
Not listed No phase listed Observational

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

NCT04115436
View directory record Official record
Conditions
Thromboembolic Events
Interventions
Not listed
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Not applicable Interventional

SIMPLAAFY Clinical Trial

NCT06521463
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Terminated Not applicable Interventional

Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

NCT01668953
View directory record Official record
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
Platelet Rich Plasma (PRP) Injection, Whole Blood Injection, Dry Needle Fenestration, Sham Injection
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Withdrawn Phase 4 Interventional

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

NCT02123498
View directory record Official record
Conditions
Eustachian Tube Dysfunction, Laryngopharyngeal Reflux
Interventions
Omeprazole, Ranitidine, Pantoprazole, 24-Hour Diagnostic pH-Probe Test, Laryngoscopy
Drug · Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Loma Linda, California • Redlands, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 13, 2026, 9:14 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 13, 2026, 9:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

NCT04593030
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
220,518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 13, 2026, 9:14 PM EDT
Completed No phase listed Observational

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

NCT04736420
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
78,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Evaulation of Interaction Between Herbal Products and Anticoagulants

NCT00071682
View directory record Official record
Conditions
Coagulation Disorders
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 13, 2026, 9:14 PM EDT
Not listed Phase 4 Interventional

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

NCT04169269
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters, Rivaroxaban 10 milligram Oral Tablet
Drug
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 13, 2026, 9:14 PM EDT
Not listed Not applicable Interventional

EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)

NCT05151172
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
endovascular thrombectomy (EVT), Standarad medical care
Device · Other
Lead sponsor
Dr. Michael D Hill
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • San Francisco, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 13, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NCT06957366
View directory record Official record
Conditions
Atrial Fibrillation (AF), VTE
Interventions
PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330
View directory record Official record
Conditions
Thromboembolism
Interventions
dabigatran etexilate 150 mg, warfarin (INR 2-3)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
23
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 13, 2026, 9:14 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Not yet recruiting Phase 4 Interventional

Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma

NCT07116395
View directory record Official record
Conditions
Patients Undergoing Operative Fixation of Long Bone Fractures Within the Community Medical Centers System
Interventions
Tranexamic Acid (TXA)
Drug
Lead sponsor
Arbi Nazarian, MD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Response to Warfarin in Healthy Subjects

NCT01520402
View directory record Official record
Conditions
Healthy
Interventions
Warfarin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 74 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Not applicable Interventional

Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department

NCT01518335
View directory record Official record
Conditions
Sprain of Ankle
Interventions
Platelet rich plasma injection, Placebo Comparator: Placebo/Standard of Care
Procedure
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 13, 2026, 9:14 PM EDT